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ARTICLE
Fast acting allosteric phosphofructokinase
inhibitors block trypanosome glycolysis and cure
acute African trypanosomiasis in mice
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Scott P. Webster4, Nick Gray1, Peter M. Fernandes 1, Elmarie Myburgh 5, Elizabeth A. Blackburn 1,
Ryan Ritchie6, Carol Austin2, Martin A. Wear1, Adrian J. Highton2, Andrew J. Keats2, Antonio Vong2,
Jacqueline Dornan1, Jeremy C. Mottram 7, Paul A. M. Michels 1, Simon Pettit2✉ &
Malcolm D. Walkinshaw 1✉
The parasitic protist Trypanosoma brucei is the causative agent of Human African Trypano-
somiasis, also known as sleeping sickness. The parasite enters the blood via the bite of the
tsetse fly where it is wholly reliant on glycolysis for the production of ATP. Glycolytic
enzymes have been regarded as challenging drug targets because of their highly conserved
active sites and phosphorylated substrates. We describe the development of novel small
molecule allosteric inhibitors of trypanosome phosphofructokinase (PFK) that block the
glycolytic pathway resulting in very fast parasite kill times with no inhibition of human PFKs.
The compounds cross the blood brain barrier and single day oral dosing cures parasitaemia in
a stage 1 animal model of human African trypanosomiasis. This study demonstrates that it is
possible to target glycolysis and additionally shows how differences in allosteric mechanisms
may allow the development of species-specific inhibitors to tackle a range of proliferative or
infectious diseases.
https://doi.org/10.1038/s41467-021-21273-6 OPEN
1Wellcome Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Michael Swann Building, Max Born Crescent, Edinburgh, UK.
2 Selcia Ltd., Fyfield Business and Research Park, Fyfield Road, Ongar, Essex, UK. 3 Cambridge MedChem Consulting, Cambridge, UK. 4 Centre for
Cardiovascular Science, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK. 5 York Biomedical Research Institute, Hull York
Medical School, University of York, York, UK. 6 Institute of Infection Immunity and Inflammation, College of Medical Veterinary Life-Sciences, University of
Glasgow, Glasgow, UK. 7 York Biomedical Research Institute, Department of Biology, University of York, York, UK. 8These authors contributed equally:
Iain W. McNae, James Kinkead, Divya Malik. ✉email: simon.pettit@selcia.com; m.walkinshaw@ed.ac.uk









Human African trypanosomiasis (HAT), also known assleeping sickness is caused by two subspecies of theparasitic protist Trypanosoma brucei and is transmitted
by the bite of an infected tsetse fly1. The subspecies T. b. gam-
biense, prevalent in west and central Africa is responsible for over
97% of cases with the remainder caused by T. b. rhodesiense in
eastern and southern Africa2,3. HAT has two stages: the first,
haemolymphatic stage includes non-specific symptoms, such as
headache and bouts of fever. The second stage occurs when the
parasite has invaded the central nervous system (CNS), leading to
progressive mental deterioration and ultimately death. There are
five registered drugs currently used to treat HAT; all have a
number of drawbacks, including severe side effects associated
with significant toxicity/mortality or prolonged and complex
dosing regimens, including a requirement for intravenous
administration4. A new oral drug, fexinidazole has recently been
given approval for use in the clinic (https://www.dndi.org/
diseases-projects/portfolio/).
The bloodstream form (BSF) of T. brucei has evolved to rely on
the high (5 mM) levels of glucose available in host blood as fuel.
In this stage of its life cycle, the parasite mitochondrion is highly
compromised and cannot carry out oxidative phosphorylation
and T. brucei exclusively uses glycolysis as the sole source of ATP.
Our hypothesis was therefore that the glycolytic pathway would
be a suitable target for small molecule anti-HAT drugs. As proof
of concept, RNA interference-mediated knockdown experiments
showed that even a 50% decrease in glycolytic flux is sufficient to
kill the parasite in vitro5. T. brucei phosphofructokinase (TbPFK)
is located in peroxisome-related organelles called glycosomes6
and carries out the third step in the glycolytic pathway, phos-
phorylating fructose 6-phosphate (F6P) to give fructose 1,6-
bisphosphate (F16BP) (Fig. 1). Low sequence identity of ~20%
with the three human isoforms (hPFK-M, hPFK-L and hPFK-P)
despite sharing very similar active sites7 supported the choice of
this target.
The first published example of a TbPFK inhibitor was a
dichlorophenyl-furanose derivative, which showed weak (IC50=
23 µM) inhibition8. A subsequent high-throughput screen (HTS)
against TbPFK using a library of over 330,000 compounds9
from the Molecular Libraries Small Molecule Repository, identi-
fied over 500 active compounds (https://pubchem.ncbi.nlm.nih.
gov/bioassay/485367). The most potent compounds in this screen
all contained a dichlorophenyl group. A convincing structure–
activity relationship (SAR) showing the importance of the di-
substituted phenyl group was developed and a series of com-
pounds was synthesised, using an amidosulfonamide scaffold
linked to the substituted phenyl group10. One of the best com-
pounds in this series (CTCB-001, Fig. 2) had an IC50 value of
~200 nM. This series of compounds also inhibited Trypanosoma
cruzi PFK and showed up to fivefold better potency compared
with TbPFK. However, the compounds were not effective at
killing either the T. cruzi or T. brucei parasites in in vitro culture
with poor EC50 values of at best ~20 µM, presumably due to poor
uptake by the parasites10.
In this study, we show how an X-ray structure-based design
approach has led from an initial high-throughput screening hit to
the synthesis of a series of a highly specific inhibitors against the
trypanosome PFK that block glycolysis in the parasite, but have
no effect on the human enzyme. Enzymatic and kinetic studies
further show that the mechanism of action is allosteric and the
inhibitors do not compete with ATP in the active site. Consistent
with the mechanism, we show that the inhibitors have a very fast
parasite killing time. The lead compounds have good pharma-
cokinetic (PK) profiles with excellent bioavailability. Studies with
trypanosome-infected mice show the compounds readily pene-
trate the brain and that oral dosing can cure acute infection.
Results and discussion
Bioactive lead compounds were developed using a structure-
based approach. We used the SAR results of our previous stu-
dies10 to select a small number of readily available fragment-like
molecules that contained the dichlorophenyl pharmacophore.
Each compound was tested in vitro in an enzyme inhibition assay
and in a parasite killing assay (see ‘Methods’ and Supplementary
Fig. 1) leading to the identification of CTCB-12, which potently
inhibited TbPFK with an IC50 value of 0.83 µM and high ligand
efficiency of 0.51 (Fig. 2). It was also possible to co-crystallise
CTCB-12 with TbPFK. The X-ray structure of this complex
shows that the di-substituted phenyl group fills a deep allosteric
pocket adjacent to the active site (Fig. 3), and explains the ubi-
quitous presence of the dichlorophenyl pharmacophore in hits
from the HTS run. Based on the X-ray structure of CTCB-12, a
number of derivatives were synthesised using pyrazole and
bicyclic scaffolds, including imidazopyridines, pyrazolopyridines,
thienopyridines and pyrrolopyridines, and tested against an
enzyme inhibition assay and an in vitro parasite killing assay
(Fig. 4). Over 30 X-ray structures of TbPFK complexed with
ligands from most of the different scaffold families have been

































Fig. 1 Glycolysis in bloodstream form T. brucei. The first seven enzymes
of the glycolytic pathway, from hexokinase to phosphoglycerate kinase, are
sequestered in peroxisome-related organelles called glycosomes. Glucose,
taken up by the trypanosome from the blood, enters the glycosomes and is
converted stepwise via glucose 6-phosphate (glc-6-P), fructose 6-phosphate
(fru-6-P), fructose 1,6-bisphosphate (fru-1,6-BP), glyceraldehyde 3-phosphate
(G-3-P) and glycerate 1,3-bisphosphate (G-1,3-BP), which is the precursor
of 3-phosphoglycerate (3-PGA) that exits the organelles. The last three
steps occur in the cytosol with the conversion of 3-PGA to 2-PGA, the
precursor of phosphoenolpyruvate (PEP) which is converted to pyruvate.
Inside glycosomes, the use of ATP by hexokinase and PFK, and its formation
by phosphoglycerate kinase are balanced. Net ATP synthesis by pyruvate
kinase occurs in the cytosol. NADH formed inside the glycosomes by
glyceraldehyde-3-phosphate dehydrogenase is re-oxidised by a glycosomal
NADH-dependent glycerol-3-phosphate dehydrogenase, an electron shuttle
involving glycerol 3-phosphate (glyc-3-P) and dihydroxyacetone phosphate
(DHAP), and a mitochondrial FAD-dependent glycerol-3-phosphate oxidase
system not coupled to ATP synthesis. The trypanosomes can also take up
glycerol, to be converted into pyruvate with a net ATP synthesis of 1 ATP/
glycerol, or be used in gluconeogenesis to form glucose 6-phosphate.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21273-6
2 NATURE COMMUNICATIONS |         (2021) 12:1052 | https://doi.org/10.1038/s41467-021-21273-6 | www.nature.com/naturecommunications
dichlorophenyl group locked in the allosteric pocket as observed
in the structure with CTCB-12.
The most efficacious group of compounds were derivatives of a
pyrrolopyridine scaffold with amino side chains on N5 (Fig. 5).
Ethylamino substituents were found to have the best inhibitory
activities, with IC50 values as low as 30 nM (CTCB-421, Fig. 2). X-
ray structures of this series show that the amino side chain sub-
stituent on N5 bends to make a hydrogen bond with Asp199
(Fig. 5b). This binding mode is further stabilised by a short (3.1 Å)
electrostatic interaction between the negative carboxyl oxygen and
the CTCB-405 amide carbon atom. The X-ray complexes clearly
explain the SAR that strictly limits the size of substituents on the
phenyl ring (Fig. 5a). Chlorine in the meta position is ideally
positioned to make a specific electrostatic interaction with a car-
bonyl oxygen of Gly197 lining the allosteric pocket (Fig. 5b). The
geometry of this ‘halogen bond’ with a Cl…O distance of 3.3 Å
Fig. 2 Optimisation of the CTCB series of inhibitors of TbPFK. IC50 values (µM) for inhibition of T. brucei phosphofructokinase. EC50 values (µM) for
in vitro parasite killing of the bloodstream form of T. brucei strain Lister 427 (see Supplementary Methods 2.1 and 4.2). L.E. ligand efficiency. IC50 values are
based on at least three independent measurements (‘biological replicates’). EC50 values were initially determined from two technical replicates. Estimated
standard deviations (ESDs) for selected compounds were determined using biological replicate studies (n≥ 3). The pKa values were calculated using
ChemAxon software and categorised assuming physiological pH of 7.8 (Supplementary Table 6). The figure shows that there is a better translation from
IC50 to EC50 for the more basic molecules. a The path to identifying the chemical scaffold used for lead compound development CTCB-001, the starting
point for this work, was identified from a high-throughput screen as a good enzyme inhibitor but with poor trypanocidal activity10. b Inhibition data for
derivatives of the pyrrolopyridine series. Details of the synthesis and characterisation of CTCB-405, CTCB-470 and CTCB-508 are given in Supplementary
Methods 7 and 8. Source data for IC50 and EC50 values are provided as a Source Data File.
3a 3b
Fig. 3 Architecture of the TbPFK target and X-ray structure of the complex with CTCB-12. a Tetrameric structure of TbPFK. The four TbPFK chains
making the TbPFK tetramer are coloured (yellow, green, orange and purple). The boxed region shows the position of the active site with ATP modelled
in position (carbon atoms shown as white-coloured thick sticks). The fragment CTCB-12 is in the adjacent allosteric pocket shown in pink, chlorine atoms
are green). Part of the mobile activating loop (residues 225PKTIDNDLSFS235) is highlighted in black. b Blow up of the boxed region showing the
dichlorophenyl binding pocket in TbPFK complexed with fragment structure CTCB-12 with the dichlorophenyl ring filling the allosteric pocket. ATP is also
shown coordinated to magnesium (blue sphere). Two residues from the mobile activating loop (L232 and D231) are in black. The Supplementary Movie 1
shows how the CTCB compounds block activation and prevent the side chain of L232 moving into the allosteric pocket, stopping the mobile activating loop
adopting the active R-state conformation, which brings D231 and D229 within coordinating distance of the substrate molecules. Supplementary Figure 7
shows stereo diagrams with electron density contoured round CTCB-12, CTCB-360 and CTCB-405.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21273-6 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:1052 | https://doi.org/10.1038/s41467-021-21273-6 | www.nature.com/naturecommunications 3
and C–Cl–O angle of 150° is in the expected range11. Other
permutations of Br and F substituents on the phenyl group were
found to have a small effect on binding affinity, but showed sig-
nificant effects on PK behaviour.
Isothermal titration calorimetry (ITC) results show that all of
the CTCB compounds bind with an almost perfect 1:1 stoichio-
metry with TbPFK (Supplementary Fig. 5). The main binding
contribution for the series is enthalpic with a relatively minor
unfavourable entropic contribution. For CTCB-405, the ΔG of
−9.57 kcal mol−1 comprises ΔH=−13.6 kcal mol−1 with a TΔS
contribution of −4.03 kcal mol−1. The Kd values match well with
the surface plasmon resonance (SPR) results; CTCB-405 has a Kd
of 92 nM (ITC) compared with 82 nM (SPR). SPR data (Sup-
plementary Fig. 6) also show that the CTCB compounds have
fast on rates (konCTCB-405= 0.96 µM−1 s−1) and slow off rates
(koff= 0.079 s−1).
The compounds in Fig. 4 are coded to show the variety of
chemical scaffolds that have been synthesised and tested for both
parasite killing and TbPFK inhibition (further details of synthetic
routes and chemical characterisation for many of these TbPFK
inhibitors are available in a published patent application12). The
parasite killing assay uses the fluorescent signal from the redox
indicator Alamar Blue as a measure of cell viability, and the
generally good correlation between IC50 versus EC50 fits with
TbPFK being the target for the CTCB compound series. There is
little evidence for off-target effects in which the EC50 killing
concentration could be expected to be less than the IC50 enzyme
inhibition concentration. Deviation from a direct correlation
(where EC50 > IC50) can be rationalised by poor uptake of the
compound into the parasites or into the glycosome organelles
that contain TbPFK. The series of basic molecules (coloured
green in Fig. 4) show good correlation of IC50 (PFK inhibition)
with EC50 (parasite killing). However, neutral compounds (shown
in red) or acidic compounds (shown in blue) have significantly
poorer EC50 values. The effect of pKa on parasite killing seems to
be consistent for a wide variety of structural classes. The converse
observation that small chemical changes affecting pKa can cause
significant changes in EC50 values also supports the idea that
basicity plays an important role in uptake and killing. For
example, when the dimethylamino group of compound CTCB-
405 is replaced by a hydroxyl group (CTCB-401, Fig. 2), the
neutral compound CTCB-401 inhibits the enzyme more effec-
tively with an IC50 of 73 nM (compared with 180 nM for CTCB-
405), while it is less effective against the parasite with an EC50 of
900 nM compared with 370 nM for the more basic CTCB-405. X-
ray structures of both compounds show the same binding pose.
As shown in Figs. 2 and 4, all of the more potent compounds have
pKa >8 and include primary amines (e.g., CTCB-421 and CTCB-
457) and secondary amines (e.g., CTCB-435 and CTCB-481).
Despite the potency against the parasites, subsequent ADME and
toxicity studies showed these generally more basic compounds
had a less suitable profile than the tertiary amine lead compounds
CTCB-405, CTCB-470 and CTCB-508 which, though not having
the lowest IC50 or EC50 values, were found to have the best
combination of in vitro and in vivo properties. Importantly, the
lead compounds also show good activity against the human
pathogens T. b. gambiense and T. b. rhodesiense with EC50 values
between 150 and 250 nM, showing even slightly better potency
than against the T. b. brucei Tb427 and TbGVR35 laboratory
strains (Supplementary Table 4).
Structural, enzymatic and binding studies of TbPFK char-
acterise the inhibitory mechanism. Trypanosomatid PFKs have
been characterised by X-ray crystallography and two conforma-
tional states have been identified that fit with a classical
description of an allosteric enzyme that transitions from an
inactive T-state conformation to an active R-state conforma-
tion13. Comparison of the T-state and R-state structures show
that activation of TbPFK requires a large movement of the critical
catalytic residues Asp229 and Asp231 (Fig. 3 and Supplementary
Movie 1). The carboxyl groups of the two Asp residues hydrogen
bond with the F6P substrate and also coordinate a catalytic
magnesium ion, facilitating transfer of a phosphoryl group from
ATP. The mobile activating loop is locked in its active R-state by
the side chain of Leu232, which sits on the same mobile loop and
fits into the allosteric drug-binding pocket (Fig. 3 and Supple-
mentary Movie 1). The mode of action for the CTCB family of
inhibitors is to lock the tetramer in the inactive T-state, with the
activation loop held remote from the substrate molecules.
Enzyme kinetic studies confirmed that the CTCB compounds
are not competitive against either ATP or F6P. TbPFK inhibition
was studied using an enzyme assay, in which production of ADP
by TbPFK was coupled to the reactions of pyruvate kinase and
lactate dehydrogenase: the conversion of pyruvate to lactate and
NADH to NAD+, is monitored by reduction of UV absorbance at
340 nm. The Michaelis–Menten plots (Supplementary Fig. 2 and
Supplementary Table 1) show inhibitory behaviour for the
compound CTCB-405, which is typical for the compound series.
The reduction of Vmax for both substrates (F6P and ATP)
indicates that the inhibitor is not competitive with either ATP or
F6P. This is consistent with the X-ray structures showing no
steric overlap between the substrate binding sites and the CTCB
inhibitor binding site.
Divergent allosteric mechanisms of hPFK and TbPFK explain
the species specificity of the CTCB compounds. Of the 19 resi-
dues that bind the ATP and F6P substrate molecules, 12 are
Fig. 4 EC50 versus IC50 values for CTCB compounds. Each compound in
the CTCB series was tested against T. brucei in an in vitro killing assay and
also tested in an enzyme inhibition assay against TbPFK. The Y-axis-
labelled Tbb_427_gi gives the EC50 values for the growth inhibition assay
(Supplementary Methods 4) and the X-axis-labelled Tbb_PFK_ADPglo
gives IC50 values for the enzyme inhibition assay (Supplementary
Methods 2.1). The compounds are colour coded according to charge
(green= basic, red= neutral and blue= acidic). The plot shows that for a
wide variety of structural classes (denoted by shape of the data point),
there is a better translation from IC50 to EC50 for the basic molecules and
that the effect of pKa on parasite killing appears to be consistent across
different structural classes (though only details of the pyrrolopyridine class
are described in this communication). The pKa values were calculated using
ChemAxon software and categorised assuming physiological pH of 7.8.
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conserved between human and TbPFK. However, the overall
sequence identity between the two orthologues is only 20%.
Human PFK isoforms are tetramers with chain length of ~780
amino acids and have additional regulatory domains responsible
for a very different allosteric regulatory mechanism compared
with the smaller 487 residues long TbPFK14. The allosteric pocket
regulating the switch between T- and R-states in the TbPFK is not
present in any of the hPFK isoforms (Supplementary Fig. 3 and
Supplementary Movie 2). The inhibitory mechanism of the pyr-
rolopyridine compounds is therefore exquisitely specific for try-
panosomatid PFK with no effect against any of the three hPFK
isoforms even at concentrations above 100 µM (Fig. 6 and Sup-
plementary Fig. 4).
The time-to-kill (TTK) assay shows very fast parasite killing.
As predicted from the biology of the BSF that relies wholly on
glycolysis for ATP production, inhibition of the pathway results
in a very fast TTK. Two experimental methods were used to
measure ATP levels as a real-time indicator of viability. For
Tb427 parasites, a Cell Titre Glo kit was used and for the
TbGVR35 bioluminescent strain, killing was assessed by adding
luciferin which requires ATP to produce a luminescent signal
(Supplementary Methods 4.3 and 4.4). Both assays show that for
the lead CTCB series, over 99% of parasites are killed in under
30 min at a concentration of 4 µM (Fig. 6b). The BSF of T. brucei
cannot produce ATP by oxidative phosphorylation and is solely
dependent on flux through the glycolytic pathway. The clear
correlation between inhibitor dose and reduction in ATP pro-
duction, as observed in the TTK assays strongly supports the
proposed mode of action of the CTCB compounds is by blocking
glycolysis. It is a long-established experimental observation that
withdrawal of glucose nutrient leads to rapid loss of motility and
cell death15. It has recently been shown that the BSF of T. brucei
can proliferate on high levels of glycerol; however, we have shown
that addition of glycerol to the medium has little effect on parasite
killing by the CTCB compounds (Supplementary Table 3). The
very fast (t0.5 < 15 min) parasite killing linked to loss of ATP
production (Fig. 6b) caused by the CTCB compounds is therefore
wholly consistent with the direct inhibition of one of the glyco-
lytic enzymes. This mode of action resulted in a much faster kill
than any of the other trypanocidal compounds tested in our
assay, including fexinidazole, suramin and those of the oxaborole
family, which all have TTK values >20 h.
In order to estimate a killing-dose for in vivo trials, a series of
washout experiments were carried out: parasites were incubated
with a given concentration of compound before washing out the
drug and determining whether the parasites were still viable and
able to proliferate. The results showed that even though >99% of
parasites were killed within 30 min, a longer exposure of between
2 and 4 h at concentrations of 2–4 µM was required to ensure
100% killing in vitro (Supplementary Fig. 8). The existence of a
small population of parasites more resistant to the effects of the












X,Y: 3,4-di-Cl = 3-Cl-4-F
= 3-Br-4-F = 3-CN-4-Cl 
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5a
5b
Fig. 5 Structure–activity relationship of the CTCB allosteric inhibitors and binding interaction of the lead CTCB series. a Structure–activity of the
pyrrolopyridine scaffold. Three regions in the structure are highlighted in green, blue and yellow, and the respective biological properties or activities are
indicated. b X-ray structure of CTCB-405 bound to TbPFK showing three binding features of the pyrrolopyridine lead series. The chlorine atom forms a
‘halogen bond’ with the backbone carbonyl atom from Gly (Cl…O= 3.3 Å). There is an unusual short attractive interaction between the carboxyl oxygen
atom of Asp199 and the amide carbon atom of CTCB-405 (O…C= 3.1 Å). The ethylamine side chain adopts a conformation allowing salt bridge formation
with Asp199 (N…O= 2.6 Å).
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parasites being present at different stages of the cell cycle. The
parasite cultures used in the killing experiments are not syn-
chronised, and it is likely that ATP requirement varies depending
on cell cycle phase and a subpopulation with lower ATP
requirement may be less susceptible to the CTCB compounds,
however, this phenomenon needs further investigation.
The CTCB lead compounds have good ADME and pharmaco-
kinetic (PK) profiles (Tables 1 and 2). Potential compound toxicity
was determined by measuring the ratio of EC50 values for human
HepG2 cells compared with the EC50 for parasite killing giving
values of between 40 and 110-fold selectivity (Tables 1 and 2).
CTCB-405 was very stable when tested in human liver micro-
somes, but was much less stable when tested in mouse liver
microsomes (Clint < 8.6 compared with 70 µLmin−1 mg−1).
MDR1-MDCK permeability assays showed that CTCB compounds
are not P-gp substrates and cross the endothelial membrane.
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Fig. 6 CTCB compounds are highly specific and have a very fast time-to-kill compared with all available clinical anti-HAT drugs. a CTCB-405 shows no
significant inhibition of human PFK. Enzyme activity was measured using an aldolase/TIM linked assay at 25 °C. Enzyme activities of T. brucei PFK, hPFK-M
and hPFK-P were measured as described in Supplementary Methods 2.3 (Supplementary Fig. 4 shows similar result for titrations of CTCB-508, and CTCB-
470 against hPFK-L). Experiments were carried out in duplicate. Data are presented as mean values ± standard deviation. Highest concentration of CTCB-
405= 100 μM. Source data are provided as a Source Data File. b Kill time of CTCB-405 compared with existing HAT drugs in the clinic. The cell viability
assay was used to study the effect of a fixed concentration of suramin (11 µM), fexinidazole (11 µM), SCYX-7158 (11 µM) and CTCB-405 (4 µM). Over 99%
of trypanosomes were killed in under 30min compared with much slower killing rates for the other drugs. The points on the graph for CTCB-405 were
determined from two independent biological replicate experiments with each time point measured twice (using duplicate technical replicates). The ESD for
each point on the graph is between 0.7 and 1.4%. For drugs in clinical use each point on the graph is the average of two technical replicates from one
experiment (with a maximum difference of 7.8% for any of the points). Source data are provided as a Source Data File.
Table 1 In vitro ADME profiles for CTCB-405, CTCB-470 and CTCB-508. Methods are described in Supplementary Methods 5
and 6. Enzyme assay results are means ± SD in multiple assays. ADME results are averages of n= 2 or 3 measurements in
individual assays. MLM Clint mouse liver microsome intrinsic clearance, HLM Clint human liver microsome intrinsic clearance.
Parameter CTCB-405 CTCB-470 CTCB-508
PFK IC50 (µM) (n= 4) 0.18 ± 0.03 0.22 ± 0.08 0.20 ± 0.05
Tbb EC50 (µM) (n= 2) 0.37 ± 0.04 0.31 ± 0.03 0.30 ± 0.02
ADME results
MLM Clint (µL min−1 mg−1) 70 91 56
HLM Clint (µL min−1 mg−1) <8.6 17.0 <8.6
Human hepatocytes Clint (µL min−1 per 106 cells) 2.3 nd nd
Mouse hepatocytes Clint (µL min−1 per 106 cells) 3.7 3.6 nd
HepG2 EC50 (µM) 20.8 12.3 33.4
Selectivity 56 39 111
MDCK-MDR1 A-B/B-A 17.6/17.2 34.9/28.3 —
CYP450 2C9 (% inhibition at 10 µM) 11 28.5 6.1
Human hERG IC50 (µM) 3.98 1.69 4.75
Human plasma protein binding fu(%) 6.3 3.2 21
Mouse plasma protein binding fu(%) 5.8 6.0 18
Mouse brain tissue binding fu (%) 0.8 0.6 1.7
Kp,brain 4.1 1.5 3.0
Kp,uu,brain 0.6 0.2 0.3
Brain and plasma concentrations were measured 2 h after oral doses of 50mg kg−1 (CTCB-405 and CTCB-470) and 100mg kg−1 (CTCB-508).
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Female CD-1 mice were used to establish the tolerance and efficacy
of compounds in vivo (Supplementary Methods 6).
PK parameters for the lead compounds were determined using
three mice per data point (Supplementary Methods 6.1). The
nature of the dihalogen substituents was found to have a sig-
nificant effect on oral bioavailability with values for CTCB-508,
CTCB-405 and CTCB-470 of 119%, 54% and 24%, respectively
(Table 2). CTCB-508 also has a relatively low mouse plasma
protein binding value of 82% compared with CTCB-405 (94%)
and CTCB-470 (94.2%).
The PK studies also show that the CTCB series can cross the
blood–brain barrier and enter the brain. A single oral dose of
50 mg kg−1 for CTCB-405 gives a mean plasma concentration of
366 ng mL−1 and a mean concentration in brain homogenate of
1508 ng g−1 resulting in a Kp value (ratio of total compound in
brain to total compound in plasma) of 4.1. Binding of CTCB-405
to brain tissue is about sevenfold greater than to plasma with free
fraction brain= 0.8% compared with free fraction plasma= 5.8%
(Table 1). These values for concentrations of free compound in
the brain give a Kp,uu value of 0.6 (defined as the ratio of unbound
compound in brain to unbound compound in plasma). This ratio
provides an estimate of the amount of free drug in the brain
interstitial fluid as being just over half the free concentration in
the blood.
High doses of each of the three lead compounds, CTCB-405,
CTCB-470 and CTCB-508, were well tolerated. Mice treated with
CTCB-405 at up to 300mg kg−1 per day in cumulative dosing
tolerance studies showed no apparent toxicity and autopsied livers
of mice subjected to such high doses appeared normal. A dosing
regimen with three doses of 50mg kg−1 given every 2 h resulted in
a plasma concentration of 6.8 ± 2.1 µM measured 2 h after the
final dose. A similar regimen with three doses of 100mg kg−1 gave
a plasma concentration of 9.8 ± 3.1 µM again measured 2 h after
the final dose. The predicted plasma values based on the measured
mouse PK parameters were 4.1 and 8.3 µM, respectively
(Supplementary Fig. 10 and Supplementary Table 5).
T. b. brucei Lister 427 infection is cured by 1-day dosing. The
majority of the compounds in the literature have been tested in
mice infected with the T. b. brucei Lister 427 strain, which is a
monomorphic (non-pleiomorphic) strain that grows in a virulent
and unconstrained manner and does not undergo life cycle dif-
ferentiation. These parasites have a doubling time of ~6 h 16 and
infection with 1 × 105 parasites usually requires euthanasia of
mice within 4–5 days of infection in the absence of drug
treatment. Drug efficacy is determined by taking regular blood
samples from infected mice and checking microscopically for
parasitaemia. In this model of acute infection a single surviving
parasite should proliferate to reach detectable levels in ~5 days
and a 30-day period of no parasite detection is considered as cure.
In vitro parasite killing experiments described above suggested
that in order to kill 100% of the parasites, an exposure to over
2 µM compound would be required for a period of 8 h or alter-
natively exposure to a higher total concentration of compound
of 4 µM for a shorter (6 h) period (Supplementary Fig. 8). A
simple model based on estimated bioavailability and the mea-
sured half-life of the compound in plasma showed that these
levels could be achieved by three doses of 100 mg kg−1 admi-
nistered at 2 h intervals. Experimentally, three doses of CTCB-405
at 100 mg kg−1 given on two consecutive days gave plasma levels
of 9.8 µM (Supplementary Table 5).
A number of dosing regimens for the three lead compounds
were tested against infected mice (Fig. 7a and Supplementary
Fig. 11). Four single day doses of CTCB-405 at 50 mg kg−1
delayed the onset of parasitaemia by up to 12 days; however,
thrice daily doses of 50 mg kg−1 gave a complete cure (defined as
preventing the recurrence of parasitaemia for >30 days; Supple-
mentary Fig. 11). A 1-day dosing regime was explored for CTCB-
405 with three doses of 100 mg kg−1 at 2 h intervals which also
resulted in complete cure for 5/5 infected mice.
An alternative mouse model for stage 1 (acute) and stage 2
(CNS-involved) HAT has been developed using a transgenic cell
line derived from the pleiomorphic T. b. brucei GVR35 that
expresses red-shifted firefly luciferase17,18. EC50 values of CTCB
compounds for the bioluminescent T. b. brucei GVR35 strain
determined in vitro were similar to those for T. b. brucei Lister
427. T. b. brucei GVR35-infected mice present stage 1 disease by
day 7 post infection with progression to stage 2 by day 21. By
injecting the mouse with luciferin, the level of parasitaemia can be
estimated in real time by monitoring the luminescence. Unlike
monomorphic Lister 427 T. b. brucei, the pleiomorphic GVR35 T.
b. brucei is controlled by a quorum-sensing mechanism resulting
in the significant increase in survival time in mice and lower
blood parasitaemia that occurs in waves. This extended survival
time is also accompanied by parasite dissemination to multiple
tissues and organs, including the skin, adipose tissue, lung and
brain, with parasite loads increasing over time17,19. This more
virulent strain usually requires higher or longer doses of trypa-
nocides for cure in vivo compared to the Lister 427 strain20,21,
possibly caused by reduced drug accessibility in these extra-
vascular tissues. Using this more stringent model, treatment with
CTCB-405 during stage 1 (day 7) reduced parasitaemia in the
body and blood of mice, and delayed detection of parasites in
blood to day 14 post infection. Clearance of parasitaemia is not
complete as seen with the Lister 427 monomorphic strain, but
treatment in stage 2 infection (from day 21) with CTCB-470 and
CTCB-508 showed fast and significant signal reduction in the
body (Fig. 7b). Given that the dosing regimen in place would not
result in cure of the GVR35-infected mice, the stage 2 experiment
was terminated on day 23 and brains removed. The brains of
saline-perfused mice also showed very clear reduction in para-
sitaemia (Fig. 7c, d, and Supplementary Figs. 12 and 13) con-
firming compound activity in the CNS, but without achieving
sterile parasitological cure.
The CTCB family of compounds described here have good oral
availability, cross the blood–brain barrier, are exquisitely species
specific and show very rapid parasite killing. Though more
development would be required before the CTCB compounds
could be considered as clinical candidates, the encouraging
in vivo results showing clearance of parasitaemia in the mouse
suggest that trypanosome PFK provides a new and species-
Table 2 Mouse pharmacokinetic data for CTCB-405, CTCB-
470 and CTCB-508.
CTCB-405 CTCB-470 CTCB-508
Route IV PO IV PO IV PO
Dose (mg kg−1) 1 5 1 10 1 10
Elimination t1/2 (h) 2.7 3.1 0.7
AUC (infinity)
(ng-h mL−1)
260 704 657 1565 349 4170
Cmax (ngmL−1) 206 393 1333
Tmax (h) 0.3 0.5 2.0
Vd (area) (L kg−1) 12.3 6.9 2.9




Pharmacokinetic parameters of the compounds in plasma were calculated from the curves using
PKSolutions software. Compounds were administered either intravenously or orally at the doses
indicated (n= 1 for each compound). ‘Methods’ are described in Supplementary Methods 6.1
and Supplementary Fig. 9).
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specific drug target for parasite infection. The glycolytic pathway
is one of the oldest and best-conserved cellular pathways across
both eukaryotes and prokaryotes. This high degree of conserva-
tion along with the ubiquitous presence of phosphorylated sub-
strates has made enzymes in this pathway unappealing and as yet
unexploited as drug targets. However, though the active sites of
most of the enzymes in the pathway have been conserved among
different organisms, the allosteric mechanisms that regulate each
step have evolved and diverged so that each organism can
uniquely regulate and tune the pathway to suit their individual
biological niche. This paper provides the first example of a family
of drug-like molecules that specifically inhibit this pathway and
opens up the possibility of developing more families of species-
specific inhibitors. In particular, there are opportunities to
explore the sophisticated allosteric regulatory mechanisms of the
human glycolytic enzymes that play an important role in cancer
and inflammation or in the inhibition or Gram-positive and
-negative bacteria, where the biological niches of pathogenic
bacteria have led to major differences in allosteric regulatory
mechanisms compared to enzymes of the host.
Methods
Enzymatic measurements. Parasite enzyme kinetic data were measured using N-
terminally His6-tagged TbPFK expressed in Escherichia coli C41 cells, using a
codon optimised gene inserted in a pET28a vector (Supplementary Methods 1).
Recombinant human PFKs were expressed in PFK-deficient Saccharomyces cere-
visiae22. PFK enzyme inhibition was measured using an ADP-GloTM assay (Pro-
mega) in a 96-well plate format (Supplementary Methods 2.1), using a
Spectramax© M5 Multimode Plate Reader to measure luminescence values which
were converted to ADP concentrations. IC50 values were determined using a sig-
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Fig. 7 CTCB compounds clear parasites in a stage 1 model of HAT infection with 1-day oral dosing and show reduction of parasitaemia in the brain in a
pleiomorphic model. a Kaplan–Meier survival curve depicting cure in T. b. brucei Lister 427-infected mice treated with CTCB-405 (solid line, blue), with no
recurrence of parasitaemia 30 days post infection. Three doses of CTCB-405 at 100mg kg−1 were administered 2 h apart on a single day (n= 5). The
curves also demonstrate either complete clearance or a significant increase in survival of mice orally dosed thrice daily at 50mg kg−1 over 2 days (n= 5)
with CTCB-405 (solid line, black), CTCB-470 (dashed line, black) or CTCB-508 (dotted line, black) (p < 0.0001). Control mice were administered
either vehicle only (n= 3; solid line, red) or four single daily doses of 2.5 mg kg−1 pentamidine isethionate intraperitoneally (n= 3; solid line, grey).
Survival of mice was assessed for 30 days post infection. Mice were euthanised upon detection of first visible parasites in blood samples by microscopy.
b Bioluminescence live imaging of T. b. brucei GVR35 after treatment (day 23) to evaluate parasitaemia in vivo. Infected mice were treated topically with
three doses of 3.6 mg melarsoprol over 3 days (n= 3) or orally with six doses of CTCB compounds (CTCB-470 or CTCB-508) at 100mg kg−1 over 2 days
(n= 6, only three mice from each batch are shown; Melarsoprol is a toxic anti-stage 2 HAT drug used as a positive control). Whole body bioluminescence
(total flux in photons per second, above image) and blood parasitaemia (in parasites mL−1, below image) for three representative mice from each group is
shown. c At day 23 mice shown in b were perfused with saline; brains were removed, soaked in luciferin and imaged to detect bioluminescent parasites
(bioluminescence of brains imaged ex vivo on day 23 quantified in Supplementary Fig. 12 and side head images of mice shown in Supplementary Fig. 13).
d Whole body bioluminescence pre- (day 21) and post-treatment (day 23) of infected mice shown in b (n= 3 for untreated and melarsoprol-treated mice
and n= 6 for both CTCB-470 and CTCB-508-treated mice).
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action studies were carried out using a linked enzyme assay coupling the forward
reaction of TbPFK to the M1 isoform of human pyruvate kinase followed by lactate
dehydrogenase. The change in UV absorbance at 340 nm resulting from the con-
version of NADH to NAD+ was measured at 25 °C in ‘kinetic mode’ on a Spec-
tramax© M5 Multimode plate reader. Initial velocities were plotted against
substrate concentration to give curves showing non-competitive inhibition (Sup-
plementary Fig. 2). An alternative linked enzyme assay was developed to control
for the potential inhibitory activity of ATP on human PFK (Supplementary
Methods 2.3).
Biophysical binding studies. ITC experiments were carried out in HBS buffer
(10 mM HEPES, 150 mM NaCl, 0.005% surfactant p20, pH 7.4, 1% DMSO).
Protein stocks were desalted (HiTrap 5 mL desalting column, GE Healthcare) with
the above buffer to ensure minimal buffer mismatch between ligand and analyte.
Compound titrations consisted of 16 injections with 180 s delay between injections
and 750 r.p.m. stirring at 25 °C. All solutions were degassed prior to use. A typical
ITC trace showing 1:1 binding stoichiometry is shown in Supplementary Fig. 5.
SPR measurements were performed using a BIAcore T200 instrument (GE
Healthcare). Active N-terminally His6-tagged TbPFK surfaces were generated using
a His-tag capture and coupling onto Ni2+‐nitrilotriacetic acid sensor chips.
Following Ni2+ priming (30 s injection of 500 μM NiCl2 at 5 μl min−1), dextran
surface carboxylate groups were minimally activated by an injection of 0.2 M EDC;
50 mM NHS at 5 μl min−1 for 240 s. TbPFK (at concentrations between 10 and
400 nM), in 10 mM NaH2PO4, pH 7.5; 150 mM NaCl; 50 μM EDTA; 0.05%
surfactant p20, was captured via the hexa-His-tag and simultaneously covalently
stabilised to between 1500 RU and 3100 RU, by varying the contact time.
Immediately following the capture/stabilisation a single 15 s injection of 350 mM
EDTA and 50 mM imidazole in 10 mM NaH2PO4, pH 7.5; 150 mM NaCl; 50 mM
EDTA; 0.05% surfactant p20, at 30 μl min−1, was used to remove non-covalently
bound protein, followed by a 180 s injection of 1M H2N(CH2)2OH, pH 8.5 at
5 μl min−1. A sensorgram for CTCB-405 titrated against TbPFK is shown in
Supplementary Fig. 6.
Protein X-ray structural studies. N-terminally His6-tagged TbPFK was con-
centrated to 6 mgmL−1 and crystallised via hanging drop at 290 K. The well
solution consisted of 9.5% PEG, 8000, 0.1 M sodium cacodylate pH 7.4. Crystals
formed after 3 weeks. To obtain the complex with CTCB-12, apo-crystals were
transferred to a 1 µL drop containing well solution,1 mM CTCB-12 and 1% v/v
DMSO for 10 min before being flash cooled directly in liquid nitrogen. Co-crystals
of CTCB-360 were obtained from an initial screen using the Molecular Dimensions
Morpheus crystallisation screen. Data for complexes of CTCB-12, CTCB-360 and
CTCB-405 were collected at the Diamond synchrotron radiation facility on
beamlines I03, I04 and I24, respectively. Details of the data collection, structure
determination and refinements are given in Supplementary Methods 3.3 and
Supplementary Table 2 along with stereo figures (Supplementary Fig. 7) showing
the 2|Fo|− |Fc| electron density for the three ligands.
In vitro parasite killing assays. The ‘in vitro’ parasite killing assay used the BSF of
the non-human pathogenic subspecies T. b. brucei, strain Lister 427, cultured in
HMI-9 medium containing 10% foetal bovine serum. A second cell line, T. b. brucei
GVR35-Luc2 which constitutively expresses firefly luciferase was grown in Mod-
ified HMI-9 plus 20% foetal calf serum supplemented with 20% Serum Plus
(Sigma) and 0.15 μg mL−1 puromycin. Both strains of trypanosomes were cultured
in T-25 vented cap flasks at 37 °C and 5% CO2.
The killing time of T. b. brucei Lister 427 was assessed using the CellTiter Glo
3D kit (Promega) to measure trypanosome ATP levels as a real-time indicator of
viability. Compounds of interest were serially diluted from 16 to 0.5 µM in HMI-9
medium and added into a sterile white, flat bottom 96-well plate (Greiner Inc.). A
total of 2500 trypanosomes were added to each well. The plates were incubated at
37 °C and 5% CO2. At the end of each incubation period, CellTiter Glo 3D reagent
was added to lyse the trypanosomes and the plates were incubated in the dark for
10 min at RT. Luminescence was measured at a wavelength of 580 nm using a
BMG plate reader, and percentage cell viability versus incubation time was
determined. Further details of TTK assays for the T. b. brucei GVR35-Luc2 strain,
the effect of glycerol on the EC50 values, and the in vitro ‘washout’ studies to
determine the reversibility of the action of the CTCB compounds on trypanosomes
are given in Supplementary Methods 4, Supplementary Table 3 and Supplementary
Fig. 8.
In vitro and in vivo pharmacokinetic and efficacy studies. A HepG2 cytotoxicity
assay was used to determine a cellular selectivity index. HepG2 cells were seeded
into 96-well plates in EMEM medium. Compounds were assessed for their effect
upon cellular viability (Supplementary Methods 5.1). Inhibition of CYP450 was
determined using kits from BD Biosciences (Supplementary Methods 5.2). Meta-
bolic stability was determined using mouse and liver microsomes tested at a single
concentration of 5 µM. Plasma protein binding was determined using mouse and
human plasma at a single concentration of 10 µM (Supplementary Methods 5.4).
All PK studies in mice were carried out by Pharmidex (Supplementary
Methods 6.1).
All efficacy studies were carried out using CD-1 mice in accordance with the
United Kingdom Animals (Scientific Procedures) Act (1986) under Home Office
regulations. Studies were performed in SPF facilities at the University of Edinburgh
under licence PPL 70/8102 and at the University of Glasgow under PPL 60/4442.
The experiments were approved by the local ethics committees of the respective
universities. Dosing regimens used in efficacy studies were first tested for tolerance
in female CD-1 mice (University of Edinburgh; 6–8 weeks old). Animals were
dosed orally by gavage with CTCB compounds following the dosing regimen for
each individual experiment (n= 5; Supplementary Methods 6.2).
For the mouse model of stage 1 HAT T. b. brucei Lister 427 parasites (1 × 105)
were injected into a single donor female CD-1 mouse (University of Edinburgh;
6–8 weeks old) intraperitoneally in D-PBS containing 10 mM glucose. Parasites for
subsequent stage 1 HAT infection were obtained from whole blood via cardiac
puncture, under gaseous isoflurane anaesthesia. Parasites (1 × 103) harvested from
the donor mouse were then injected into the peritoneum of female CD-1 mice
(University of Edinburgh; 6–8 weeks old) in D-PBS containing 10 mM glucose.
One day after infection, animals were either left untreated (n= 3) or dosed orally
by gavage (n= 5) with CTCB compound in Cremophor EL: EtOH: D-PBS
(30:10:60 v/v; Supplementary Methods 6.3).
For the mouse model of stage 1 and stage 2 HAT T. b. brucei GVR35-VSL2
parasites (3 × 104) were injected into a single donor female CD-1 mouse
intraperitoneally. Once infection was established, starting on day 7 for stage
1 studies and day 21 for stage 2 studies, mice were either left untreated (n= 3) or
dosed by oral gavage with CTCB compound in Cremophor EL: EtOH: D-PBS
(30:10:60 v/v; n= 6). Progression of T. b. brucei GVR35-VSL2 infection was
monitored primarily by in vivo bioluminescence imaging of infected mice using an
IVIS Spectrum (PerkinElmer). For stage 1 studies, imaging of infected mice was
performed before treatment on day 7 post infection and on days following the
treatment (days 8, 9 and 14). Imaging on groups of three mice was performed
12 min after intraperitoneal injection of 150 mg kg−1 D-luciferin (Promega) in
PBS. For stage 2 studies, mice were imaged prior to treatment on day 21, and
subsequently on days 22 and 23. On day 23, 24 h after the final dose, mice were
sacrificed by cervical dislocation and perfused with PBS containing 15 g L−1
glucose to allow ex vivo imaging of whole brains (Supplementary Figs. 12 and 13).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Structural X-ray data for protein–ligand complexes are available in the Protein Database
with accession numbers 6QU5, 6QU3 and 6QU4. Source data are provided with
this paper.
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